Legal News

Eli Lilly v Janssen—insufficiency of Alzheimer drug patent

Published on: 09 July 2013
Published by a LexisNexis IP expert

Table of contents

  • Original news
  • What is the background to this case?
  • What were the main points in this case?
  • How did the court approach obviousness?
  • How did the court decide on insufficiency?
  • Which kind of insufficiency?
  • What about the plausibility test?
  • What is the significance of events that happen after the patent filing date?
  • Are Phase II or Phase III trials most important when considering efficacy?
  • Does this case provide any principles of general application?
  • More sections of this document available when you sign-in to Lexis+ or register for a free trial.

Article summary

IP & IT analysis: Are sufficiency tests harder for pharma patents (particularly vaccines and other medicines) than for other patents?

Popular documents